Pcas: Net Sales as of Septembre 30, 2020
05 November 2020 - 6:30PM
Pcas: Net Sales as of Septembre 30, 2020
Ecully; November 5, 2020
NET SALES AS OF SEPTEMBER 30,
2020
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its net sales as at September 30, 2020.
In millions of euros |
|
2020 |
|
2019 |
|
% change |
|
2020
At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Net sales as of 30 September |
|
141.3 |
|
145.6 |
|
-3.0% |
|
141.3 |
|
-3.0% |
Pharmaceutical Synthesis |
|
96.8 |
|
89.1 |
|
8.6% |
|
96.6 |
|
8.5% |
Fine Specialty Chemicals |
|
44.5 |
|
56.5 |
|
-21.3% |
|
44.6 |
|
-21.0% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business in Health
generated €96.8 million, up 8.6% compared to 2019 (+8.5% at a
constant exchange rate). This growth can mainly be attributed to
two effects: (i) a greater operational performance at one of our
sites in the Greater Paris region and (ii) a fast mobilization of
the PCAS Pharmaceutical Synthesis division in response to the
health crisis caused by Covid-19, especially by producing a hand
sanitizer solution marketed under the Naaha brand.
Fine Specialty Chemicals
Net sales of fine specialty chemicals amounted
to €44.5 million, which was down 21.3% compared to 2019 (-21.0% at
a constant exchange rate). The Electronics business is well
resisting against the crisis, however the demand in the Lubricants
and Fine Chemicals activities has fallen significantly. The
Lubricants business in particular has been severely affected by the
health crisis.
Outlook
As mentioned in our previous press releases
since late March 2020, the global health crisis relating to the
coronavirus is changing by the day, and there are still a lot of
uncertainties regarding its duration, its extent and its effects on
companies' production lines and consumption in general.
To date, the PCAS Group has not seen any major
impacts on its business activities and earnings except for the
significant fall in demand for Lubricants and the delay in
commissioning the new production unit in Villeneuve-la-Garenne,
which was achieved mid-October 2020. The delay in commissioning the
production unit will have the effect of carrying forward
approximately €5 million of net sales to 2021. In any case, it
is still hard to anticipate the potential impacts in the medium
term. This crisis calls for cautious measures. Due to the
exceptional circumstances, the Group has suspended its financial
targets and its strategic business objectives until the situation
becomes clearer.
NEXT FINANCIAL DISCLOSURE:
Net sales at December 31, 2020 on January 28,
2021
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €200.9 million in 2019 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
Newcap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor |
Tél. : +33 1 69 79 60 00www.pcas.com |
Tél. : +33 1 44 71 98 53pcas@newcap.eu |
|
|
- PCAS - Communiqué de presse - Chiffre d'affaires au 30
septembre 2020_eng_DEF
PCAS (EU:PCA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
PCAS (EU:PCA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024